Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Next Previous
X
Search
Trial Profile

A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Gemcitabine (Primary) ; Ibrutinib (Primary) ; Lenalidomide (Primary) ; Oxaliplatin (Primary) ; Polatuzumab vedotin (Primary) ; Rituximab (Primary) ; Selinexor (Primary) ; Tafasitamab (Primary) ; Venetoclax (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Karyopharm Therapeutics

    • Most Recent Events

    • 04 Jun 2021 Status changed from recruiting to suspended.
    • 20 May 2021 Planned number of patients changed from 308 to 350.
    • 23 Dec 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top